<DOC>
	<DOCNO>NCT02115672</DOCNO>
	<brief_summary>The aim study test safety efficacy BL-8040 ( CXCR4 antagonist ) improve response imatinib CML patient achieve optimal response imatinib alone .</brief_summary>
	<brief_title>Imatinib BL-8040 ( Novel Anti CXCR4 Antagonist ) Improving Molecular Response Chronic Myelogenous Leukemia</brief_title>
	<detailed_description>To improve cytogenetic molecular response CML patient receive Imatinib , achieve optimal response accord European LeukemiaNet ( ELN ) definition , MR4 24 month Imatinib . This achieved addition CXCR4 antagonist BL-8040 , mobilize CML leukemia stem cell protective bone marrow niche expose Imatinib BL-8040-mediated apoptosis .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>1 . Adult men woman subject age 18 70 , inclusive . 2 . Confirmed diagnosis chronic phase CML accord WHO criteria ( WHO 2008 ) 3 . CML patient suboptimal response Tyrosine Kinase Inhibitors , define `` warning '' ELN recommendation : Following 3 month : BCRABL1 &gt; 10 % , and/or Ph+ 3695 % Following 6 month : BCRABL1 110 % , and/or Ph + 135 % Following 12 month : BCRABL1 0.11 % Following 24 month : Less MR4 4 . Clinical laboratory value follow : White blood cell count &lt; 30 X 10*9/L Creatinine &lt; 1.5 ULN 5 . Women childbearing potential men must agree use approved form contraception 6 . Subject able willing comply requirement protocol . 7 . Subject able voluntarily provide write informed consent . 1 . CML patient chronic phase . 2 . CML patient receive Tyrosine Kinase Inhibitors Imatinib . 3 . CML patient receive Imatinib &gt; 400 mg/day . 4 . Patients able sign inform consent . 5 . Known allergy hypersensitivity test compound material contraindication test product . 6 . Low Performance Status ( ECOG &gt; 2 ) . 7 . Abnormal liver function test : 1 . Serum aspartate transaminase ( AST/SGOT ) alanine transaminase ( ALT/SGPT ) 2 x upper limit normal ( ULN ) . 2 . Serum bilirubin . Total bilirubin &gt; 2.0 mg/dL ( 34 Âµmol/L ) , conjugate bilirubin &gt; 0.8 mg/dL 8 . Abnormal leave ventricular ejection fraction , &lt; 40 % . 9 . Subject concurrent , uncontrolled medical condition , laboratory abnormality , psychiatric illness could place him/her unacceptable risk , include , limited : 1 . Subject diagnose treated another malignancy within 3 year enrolment , except situ malignancy , lowrisk prostate , skin cervix cancer curative therapy 2 . A comorbid condition , view Investigators , render subject high risk treatment complication . 10 . Women subject pregnant breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Chronic myeloid leukemia</keyword>
	<keyword>imatinib</keyword>
	<keyword>CXCR4 antagonist</keyword>
	<keyword>BL-8040</keyword>
</DOC>